SCHEMBL2925259

SCHEMBL2925259

CC(C)c1cc(Cc2c(Br)cc(CC(=O)O)cc2Br)n[nH]c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
THRB P10828 19/20 1.00
THRA P10827 17/20 1.00
NR3C1 P04150 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13176229 0.92 THRB (0.85) THRBTHRANR3C1
SCHEMBL13176224 0.88 THRB (0.79) THRBTHRA
SCHEMBL2928572 0.86 THRB (1.00) THRBTHRA
SCHEMBL2928883 0.84 THRB (0.72) THRBTHRA
SCHEMBL2927243 0.81 THRB (0.68) THRBTHRA
SCHEMBL2928910 0.78 THRB (1.00) THRBTHRA
SCHEMBL21749446 0.75 THRB (0.59) THRBTHRA
SCHEMBL13116435 0.74 THRB (0.76) THRBTHRA
SCHEMBL13116389 0.74 THRB (0.78) THRBTHRA
SCHEMBL2929101 0.74 THRB (0.68) THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919878-B1 PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2010-09-08 EP claimed
EP-1919878-A1 PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS F. Hoffmann-Roche AG (CH) 2008-05-14 EP claimed
WO-2007009913-A1 PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-25 WO claimed
US-RE46024-E1 Thyroid hormone analogs HOFFMANN-LA ROCHE INC. (US) 2016-06-07 US disclosed
US-RE46024-E1 Thyroid hormone analogs HOFFMANN-LA ROCHE INC. (US) 2016-06-07 US disclosed
US-RE46024-E1 Thyroid hormone analogs HOFFMANN-LA ROCHE INC. (US) 2016-06-07 US disclosed
US-8399001-B2 Stabilizing compositions in suspension; fixing and holding the hair, a hair conditioner giving the hair softness, and a hair makeup L'OREAL (FR) 2013-03-19 US disclosed
EP-1532968-B1 Cosmetic composition comprising gellan gum or a derivative thereof, a monovalent salt and a compound in suspension, process using this composition and uses thereof OREAL (FR) 2013-03-13 EP disclosed
EP-2246040-A2 Method for the shaping of hair including a step of applying a reducing composition and a heating step L'Oréal (FR) 2010-11-03 EP disclosed
US-7807674-B2 Thyroid hormone analogs HOFFMANN-LA ROCHE INC. (US) 2010-10-05 US disclosed
US-7807674-B2 Thyroid hormone analogs HOFFMANN-LA ROCHE INC. (US) 2010-10-05 US disclosed
EP-1652510-A1 Cosmetic composition comprising a sulfonic polyester and a polyurethane L'OREAL (FR) 2006-05-03 EP disclosed
EP-1629827-A1 Cosmetic composition comprising a linear sulfonic polyester and a modified guar gum L'OREAL (FR) 2006-03-01 EP disclosed
EP-1629828-A1 Cosmetic composition comprising a linear sulfonic polyester and a specific polyurethane L'OREAL (FR) 2006-03-01 EP disclosed
US-20060024261-A1 Cosmetic compositions comprising a linear sulfonic polyester and a polyurethane, processes using these compositions and uses thereof L'OREAL S.A. (FR) 2006-02-02 US disclosed
WO-2005092275-A1 COSMETIC COMPOSITION COMPRISING A DENDRITIC POLYMER WITH PERIPHERAL FATTY CHAINS, A SURFACTANT AND A COSMETIC AGENT, AND USES THEREOF L'OREAL (FR) 2005-10-06 WO disclosed
US-20050196368-A1 Cosmetic composition comprising at least one anionic fixing polymer and at least one nonionic compound, and a process for shaping keratin fibers therewith by applying heat L'OREAL S.A. (FR) 2005-09-08 US disclosed
EP-1566165-A1 Process for the shaping of keratin fibers with a composition comprising an anionic fixative polymer and a non-ionic compound and using heating means L'OREAL (FR) 2005-08-24 EP disclosed
US-20050169869-A1 Cosmetic composition comprising at least one gellan gum or derivative thereof, at least one monovalent salt, and at least one suspension compound, processes using this composition, and uses thereof L'OREAL 2005-08-04 US disclosed
EP-1532968-A1 Cosmetic composition comprising gellan gum or a derivative thereof, a monovalent salt and a compound in suspension, process using this composition and uses thereof L'OREAL (FR) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050196368-A1 Cosmetic composition comprising at least one anionic fixing polymer and at least one nonionic compound, and a process for shaping keratin fibers therewith by applying heat KRT18, CUTA, INHA THRB 3284/4885THRA 2252/4885NR3C1 4561/4885
US-20060024261-A1 Cosmetic compositions comprising a linear sulfonic polyester and a polyurethane, processes using these compositions and uses thereof CUTA, FHIT, POLR1C THRB 4507/4885THRA 3816/4885NR3C1 4802/4885
US-20050169869-A1 Cosmetic composition comprising at least one gellan gum or derivative thereof, at least one monovalent salt, and at least one suspension compound, processes using this composition, and uses thereof ALG3, GYPA, ALG1 THRB 2930/4885THRA 1743/4885NR3C1 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.